Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Icosavax stock

Learn how to easily invest in Icosavax stock.

Icosavax Inc is a biotechnology business based in the US. Icosavax shares (ICVX) are listed on the NASDAQ and all prices are listed in US Dollars. Icosavax employs 34 staff and has a trailing 12-month revenue of around $4.5 million.

How to buy shares in Icosavax

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ICVX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Icosavax stock price (NASDAQ: ICVX)

Use our graph to track the performance of ICVX stocks over time.

Icosavax shares at a glance

Information last updated 2022-10-04.
Latest market close$3.22
52-week range$2.94 - $35.78
50-day moving average $5.61
200-day moving average $10.48
Wall St. target price$28.00
PE ratio 32.2
Dividend yield $0 (0%)
Earnings per share (TTM) $0.10

Buy Icosavax shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Icosavax stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Icosavax price performance over time

Historical closes compared with the close of $3.22 from 2022-10-04

1 week (2022-09-28) -3.59%
1 month (2022-09-06) -36.24%
3 months (2022-07-06) -57.69%
6 months (2022-04-06) -57.46%
1 year (2021-10-06) -90.02%
2 years (2020-10-02) N/A
3 years (2019-10-02) N/A
5 years (2017-10-02) N/A

Is Icosavax stock undervalued or overvalued?

Valuing Icosavax stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Icosavax's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Icosavax's P/E ratio

Icosavax's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Icosavax shares trade at around 32x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Icosavax's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Icosavax financials

Revenue TTM $4.5 million
Gross profit TTM $-30,974,000
Return on assets TTM -25.9%
Return on equity TTM -55.67%
Profit margin 0%
Book value $6.09
Market capitalisation $131.8 million

TTM: trailing 12 months

Icosavax share dividends

We're not expecting Icosavax to pay a dividend over the next 12 months.

Icosavax overview

Icosavax, Inc. , a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington. .

Frequently asked questions

What percentage of Icosavax is owned by insiders or institutions?
Currently 12.859% of Icosavax shares are held by insiders and 88.367% by institutions.
How many people work for Icosavax?
Latest data suggests 34 work at Icosavax.
When does the fiscal year end for Icosavax?
Icosavax's fiscal year ends in December.
Where is Icosavax based?
Icosavax's address is: 1616 Eastlake Avenue East, Seattle, WA, United States, 98102
What is Icosavax's ISIN number?
Icosavax's international securities identification number is: US45114M1099

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site